These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 35243548

  • 21. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 22. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J, Wang L, Zhan SY, Xia Y.
    Cochrane Database Syst Rev; 2012 Apr 18; (4):CD008127. PubMed ID: 22513956
    [Abstract] [Full Text] [Related]

  • 23. Ponesimod for the treatment of relapsing multiple sclerosis.
    Baldin E, Lugaresi A.
    Expert Opin Pharmacother; 2020 Nov 18; 21(16):1955-1964. PubMed ID: 32808832
    [Abstract] [Full Text] [Related]

  • 24. Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
    Zhao Z, Lv Y, Gu ZC, Ma CL, Zhong MK.
    Front Immunol; 2021 Nov 18; 12():795574. PubMed ID: 34950154
    [Abstract] [Full Text] [Related]

  • 25. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
    Chun J, Giovannoni G, Hunter SF.
    Drugs; 2021 Feb 18; 81(2):207-231. PubMed ID: 33289881
    [Abstract] [Full Text] [Related]

  • 26. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    Sriwastava S, Chaudhary D, Srivastava S, Beard K, Bai X, Wen S, Khalid SH, Lisak RP.
    J Neurol; 2022 Mar 18; 269(3):1678-1687. PubMed ID: 34800168
    [Abstract] [Full Text] [Related]

  • 27. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Li H, Hu F, Zhang Y, Li K.
    J Neurol; 2020 Dec 18; 267(12):3489-3498. PubMed ID: 31129710
    [Abstract] [Full Text] [Related]

  • 28. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
    Baker D, Forte E, Pryce G, Kang AS, James LK, Giovannoni G, Schmierer K.
    Mult Scler Relat Disord; 2023 Jan 18; 69():104425. PubMed ID: 36470168
    [Abstract] [Full Text] [Related]

  • 29. Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.
    Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, Lyons J, Mokliatchouk O, Pultz J, N'Dure F, Liu S, Badwan R, Branco F, Hood-Humphrey V, Franchimont N, Hanna J, Maghzi AH.
    JAMA Netw Open; 2022 Sep 01; 5(9):e2230439. PubMed ID: 36169959
    [Abstract] [Full Text] [Related]

  • 30. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A, Li DKB, Cascione M, Fang J, Dangond F, Miller A.
    BMC Neurol; 2018 Sep 14; 18(1):143. PubMed ID: 30217172
    [Abstract] [Full Text] [Related]

  • 31. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP, Cohen JA.
    Lancet; 2021 Sep 25; 398(10306):1184-1194. PubMed ID: 34175020
    [Abstract] [Full Text] [Related]

  • 32. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 33. Daclizumab for relapsing remitting multiple sclerosis.
    Liu J, Wang LN, Zhan S, Xia Y.
    Cochrane Database Syst Rev; 2013 Dec 23; 2013(12):CD008127. PubMed ID: 24363032
    [Abstract] [Full Text] [Related]

  • 34. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E.
    PLoS One; 2015 Dec 23; 10(6):e0127960. PubMed ID: 26039748
    [Abstract] [Full Text] [Related]

  • 35. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
    Chaudhry BZ, Cohen JA, Conway DS.
    Neurotherapeutics; 2017 Oct 23; 14(4):859-873. PubMed ID: 28812220
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL.
    Clin Ther; 2017 Aug 23; 39(8):1671-1679. PubMed ID: 28751099
    [Abstract] [Full Text] [Related]

  • 37. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
    Bravo GÁ, Cedeño RR, Casadevall MP, Ramió-Torrentà L.
    Cells; 2022 Jun 29; 11(13):. PubMed ID: 35805142
    [Abstract] [Full Text] [Related]

  • 38. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
    Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, Filippini G, La Mantia L, Repice A, Solari A, Tedeschi G, Milanese C.
    PLoS One; 2014 Jun 29; 9(11):e113371. PubMed ID: 25402490
    [Abstract] [Full Text] [Related]

  • 39. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T, Syed YY.
    CNS Drugs; 2024 Nov 29; 38(11):931-941. PubMed ID: 39368032
    [Abstract] [Full Text] [Related]

  • 40. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group.
    N Engl J Med; 2010 Feb 04; 362(5):402-15. PubMed ID: 20089954
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.